Lung cancer patients with KEAP1 mutations have shorter overall survival with poor prognosis, and KEAP1 mutant lung tumors are refractory to most available standard-of-care therapies including RT32–36, highlighting the pressing need to develop novel and effective combination therapies for this type of lung cancer. This evidence concerns the gene KEAP1 and lung cancer.